Wall St falls from latest records; auto sales soft

Image
Reuters NEW YORK
Last Updated : Mar 03 2015 | 11:48 PM IST

By Sinead Carew

NEW YORK (Reuters) - U.S. stocks fell on Tuesday after a weak auto sales report pulled the Dow and S&P back from their latest records and the Nasdaq dipped below 5,000 the day after scaling the milestone level for the first time in 15 years.

Investors exercised caution after a strong run for major indexes in February and ahead of a slew of economic data later this week, culminating with the monthly payrolls report.

For the second year in a row, tough winter weather slowed U.S. vehicle sales in February, with several major automakers missing analysts' projections and dampening bullish expectations.

"The air gets a little thin up at new highs and you need a driver to keep it going, and one of the things we are not getting as a driver today is solid auto sales," said Art Hogan, chief market strategist at Wunderlich Securities in New York.

U.S.-listed Fiat Chrysler shares fell 3.7 percent to $15.24 while Ford Motor declined 2.8 percent to $16.10. General Motors managed dropped 0.23 percent to $37.51.

"There was a lack of economic numbers to trade on," said Stephen Carl, principal and head of U.S. equity trading, The Williams Capital Group LP, in New York. "After an up market yesterday we're losing ground today."

The Dow Jones industrial average fell 130.37 points, or 0.71 percent, to 18,158.26, the S&P 500 lost 16.29 points, or 0.77 percent, to 2,101.1 and the Nasdaq Composite dropped 47.12 points, or 0.94 percent, to 4,960.97.

The Nasdaq decline was led by Microsoft Corp while Visa Inc weighed most on the Dow. Seagate Technology and Micron Technology were the worst performers in the S&P 500.

Mylan Inc fell 4.5 percent to $55.26 after the generic drug maker gave its 2015 outlook and said it may look for another acquisition after just completing a purchase of some of some overseas Abbott Laboratories' businesses last week.

MannKind Corp tumbled 9.2 percent to $6.03 after Goldman Sachs cut its rating on the drugmaker to "sell" from "neutral" and slashed its price target to $3 from $6 per share.

Declining issues outnumbered advancing ones on the NYSE by 1,957 to 1,025, for a 1.91-to-1 ratio; on the Nasdaq, 1,768 issues fell and 874 advanced, for a 2.02-to-1 ratio .

The S&P 500 was posting 8 new 52-week highs and no new lows; the Nasdaq Composite was recording 59 new highs and 27 new lows.

(Reporting by Chuck Mikolajczak; Editing by Chizu Nomiyama and Nick Zieminski)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 03 2015 | 11:30 PM IST

Next Story